Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Holding RARE?
Track your performance easily

Ultragenyx Pharmaceutical (RARE) Financial Statements

744 Followers

Ultragenyx Pharmaceutical Financial Overview

Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $-7.291; its P/E ratio is -7.16; Ultragenyx Pharmaceutical is scheduled to report earnings on February 13, 2025, and the estimated EPS forecast is $-1.35. See an overview of income statement, balance sheet, and cash flow financials.
Sep 24Jun 24Mar 24Dec 23Sep 23
Income Statement-
Total Revenue$ 139.49M$ 147.03M$ 108.83M$ 127.39M$ 98.05M
Gross Profit$ 139.49M$ 147.03M$ 108.83M$ 127.39M$ 98.05M
EBIT$ -133.21M$ -130.74M$ -136.85M-$ -159.00M
EBITDA$ -124.46M$ -118.12M$ -131.76M--
Net Income Common Stockholders$ -133.52M$ -131.60M$ -170.68M$ -123.19M$ -120.01M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 621.61M$ 763.82M$ 412.08M$ 577.21M$ 442.09M
Total Assets$ 1.54B$ 1.62B$ 1.31B$ 1.49B$ 1.24B
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -621.61M$ -763.82M$ -412.08M$ -577.21M$ -442.09M
Total Liabilities$ 1.18B$ 1.19B$ 1.17B$ 1.22B$ 1.21B
Stockholders Equity$ 346.83M$ 432.42M$ 140.26M$ 275.41M$ 31.71M
Cash Flow-
Free Cash Flow$ -68.61M$ -81.47M$ -203.94M--
Operating Cash Flow$ -67.00M$ -76.96M$ -190.73M$ -83.90M$ -117.87M
Investing Cash Flow$ -275.50M$ 60.56M$ 94.44M$ -107.02M$ 64.30M
Financing Cash Flow$ 11.17M$ 384.94M$ -58.00K$ 330.61M$ 25.23M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Ultragenyx Pharmaceutical Debt to Assets

Ultragenyx Pharmaceutical Cash Flow

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis